ArticleNutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition2025
Regression of intestinal failure-associated liver disease by alteration of lipid emulsion regime in home parenteral nutrition: A case report.
Article in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regression of intestinal failure-associated liver disease by alteration of lipid emulsion regime in home parenteral nutrition: A case report.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Up to 65% of patients receiving parenteral nutrition (PN) have intestinal failure-associated liver disease (IFALD) and ~25% will have fibrosis on biopsy. First-generation lipid injectable emulsions (ILEs) are considered a greater risk factor for IFALD compared with newer formulations. We describe a case report of an adult patient with intestinal failure receiving PN who had improvement of liver function tests (LFTs) and regression of fibrosis on liver biopsy following a switch from 100% soybean oil (SO) ILE to SO, medium-chain triglyceride, olive oil, and fish oil ILE. This supports the only other existing adult case report in the literature to date, which showed histological improvement but no improvements in LFTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.